| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.9 |